210-619-9996

Δημήτριος Α. Παππάς MD, MPH
Ειδικός Ρευματολόγος
Διευθυντής Ρευματολογικού Τμήματος, Ιατρικό Κέντρο Αθηνών
Επίκουρος Καθηγητής Ιατρικής, Columbia University Νέας Υόρκης
Πρώην Επίκουρος Καθηγητής, Johns Hopkins, Βαλτιμόρη

80+ Διεθνή Επιστημονικά Περιοδικά

80+ Διεθνή Επιστημονικά Συνέδρια

210-619-9996

ΕΠΑΓΓΕΛΜΑΤΙΚΗ ΕΜΠΕΙΡΙΑ

Οκτώβρ. 2013 – Σημερα

Διευθυντής Ρευματολογικού Τμήματος, Ιατρικό Κέντρο Αθηνών, Αθήνα, Ελλάδα

Ιούνιο 2023 – Σημερα

Αναπληρωτής Καθηγητής Ιατρικής, Ευρωπαικό Πανεπιστημιο Κύπρου, Λευκωσία, Κύπρος

Νοέμβρ. 2010 – Σήμερα

Επίκουρος Καθηγητής Ιατρικής, Ιατρική Σχολή Πανεπιστημίου Columbia, Διεύθυνση Παθολογίας, Τομέας Ρευματολογίας, Νέα Υόρκη, Νέα Υόρκη, Η.Π.Α.

Ιούλ. 2009 – Σήμερα

Επιστημονικός Διευθυντής, Consortium of Rheumatology Researchers of North America, Βοστόνη, Μασσαχουσέτη, ΗΠΑ.

Νοέμβρ. 2010 – Αυγ. 2013

Διευθυντής Κέντρου Ρευματολογικού Μυοσκελετικού Υπερήχου - Fast Arthritis Sonographic Evaluation and Treatment (FAST) Center, Διεύθυνση Παθολογίας, Τομέας Ρευματολογίας, Ιατρική Σχολή Πανεπιστημίου Columbia, Νέα Υόρκη, Η.Π.Α.

Ιούλ. 2010 – Νοέμβρ. 2010

Επίκουρος Καθηγητής Ιατρικής, Ιατρική Σχολή Πανεπιστημίου Johns Hopkins, Διεύθυνση Παθολογίας, Τομέας Ρευματολογίας, Βαλτιμόρη, Μέριλαντ, Η.Π.Α.

Ιούλ. 2009 – Ιούλιος 2010

Λέκτορας Ιατρικής, Ιατρική Σχολή Πανεπιστημίου Johns Hopkins, Διεύθυνση Παθολογίας, Τομέας Ρευματολογίας, Βαλτιμόρη, Μέριλαντ, Η.Π.Α.

Ιούλ. 2009 – Nov 2010

Συνδιευθυντής Κέντρου Ρευματολογικού Μυοσκελετικού Υπερήχου – Rapid Arthritis Care and Evaluation (RACE) Center, Ιατρική Σχολή Πανεπιστημίου Johns Hopkins, Διεύθυνση Παθολογίας, Τομέας Ρευματολογίας, Βαλτιμόρη, Μέριλαντ, Η.Π.Α.

ΕΚΠΑΙΔΕΥΣΗ

2012

Μεταπτυχιακό στη Δημόσια Υγεία (Master of Public Health – MPH), Πανεπιστήμιο Johns Hopkins, Σχολή Bloomberg Δημόσιας Υγείας, Βαλτιμόρη, Μέριλαντ, Η.Π.Α.

1999

Πτυχίο Ιατρικής Σχολής, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη, Ελλάδα

ΕΙΔΙΚΟΤΗΤΑ / ΕΞΕΙΔΙΚΕΥΣΗ

2006 – 09

Ειδικότητα Ρευματολογίας, Τομέας Ρευματολογίας, Ιατρική Σχολή Πανεπιστημίου Johns Hopkins, Βαλτιμόρη, Μέρυλαντ, Η.Π.Α.

2003 – 06

Ειδικότητα Εσωτερικής Παθολογίας, Διεύθυνση Παθολογίας, Τομέας Εσωτερικής Παθολογίας, Albany Medical College - Union University, Ώλμπανυ, Νέα Υόρκη, Η.Π.Α.

2003

Ειδικότητα Εσωτερικής Παθολογίας, Τομέας Εσωτερικής Παθολογίας, Ιπποκράτειο Πανεπιστημιακό Νοσοκομείο, Θεσσαλονίκη, Ελλάδα

ΕΡΕΥΝΗΤΙΚΗ ΔΡΑΣΤΗΡΙΟΤΗΤΑ

01/07/09 – 30/06/14

Τίτλος: Longitudinal Comparative effectiveness & Safety of Biologics in Autoimmunity (The CERTAIN study)

Χρηματοδότηση: AHRQ

Κωδικός χρηματοδότησης & χρηματικό ποσό: RO1 RO1HS018517, $2,393,997

Κύριος Ερευνητής: Curtis, Ινστιτούτο: University of Alabama

Ρόλος: Συνερευνητής & Χρηματοδότηση: Consortium of Rheumatology Researchers of North America (CORRONA)

Προσωπικός χρόνος καλυπτόμενος από τη χρηματοδότηση: 50%

Ρόλος: Επιστημονικός Διευθυντής για μελέτη CERTAIN

01/07/10 – 30/6/12

Τίτλος: RA-associated Lung Disease: Using Quantitative Markers to Improve Clinical Practice
Χρηματοδότηση: American College of Rheumatology Within Our Reach
Κύριος Ερευνητής: Danoff, Ινστιτούτο: Johns Hopkins

Προσωπικός χρόνος καλυπτόμενος από τη χρηματοδότηση: 20%

Ρόλος: Συνερευνητής

01/07/10 – 30/6/12

Τίτλος: RA-associated Lung Disease: Using Quantitative Markers to Improve Clinical Practice
Χρηματοδότηση: American College of Rheumatology Within Our Reach
Κύριος Ερευνητής: Bathon, Ινστιτούτο: Johns Hopkins
Προσωπικός χρόνος καλυπτόμενος από τη χρηματοδότηση: 20%
Ρόλος: Συνερευνητής

01/07/11 – 30/06/15

Τίτλος: Inflammation and cardiovascular disease in rheumatoid arthritis
Χρηματοδότηση: NIH/NIAMS

Κωδικός χρηματοδότησης & χρηματικό ποσό: 2R01 AR050026-07, $2,059,071

Κύριος Ερευνητής: Bathon, Ινστιτούτο: Πανεπιστήμιο Columbia
Προσωπικός χρόνος καλυπτόμενος από τη χρηματοδότηση: 10%. Ρόλος: Συνερευνητή

ΕΚΠΑΙΔΕΥΤΙΚΗ ΔΡΑΣΤΗΡΙΟΤΗΤΑ

Δημοσιεύσεις σε επιστημονικά περιοδικά

  1. Pappas DA, Taube JM, Bathon JM, Giles JT. A 73-Year-Old Woman with Rheumatoid Arthritis and Shortness of Breath. Arthritis Rheum. 2008 Jun 15;59(6):892-9.
  2. Pappas DA, Giles JT. Do Anti-tumor Necrosis Factor Agents Increase the Risk of Postoperative Orthopedic Infections?. Curr Opin Rheumatol. 2008 Jul;20(4):450-6
  3. Pappas DA, Bathon JM, Hanicq D, Yasothan U, Kirkpatrick P. Golimumab. Nature Reviews Drug Discovery. 2009 Sep;8(9):695-6
  4. Pappas DA, Gelber CA. An emerging imitator. Am J Med. 2008 Nov;121(11):952-5.
  5. Pappas DA, Geraldino-Pardilla L, Bathon JM. Immune modulation of Rheumatoid Arthritis. Best Pract Res Clin Rheumatol. 2011 Dec;25(6):873-89.
  6. Pappas DA, Giles JT, Connors G, Wise RA, Lechtzin N, Bathon JM, Danoff SK. Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study. Arthritis Res Ther. 2010 May 27;12(3):R104.
  7. Giles JT, Fert-Bober J, Park JK, Bingham CO 3rd, Andrade F, Fox-Talbot K, Pappas D, Rosen A, van Eyk J, Bathon JM, Halushka MK. Myocardial citrullination in rheumatoid arthritis: A correlative histopathologic study Arthritis Res Ther. 2012 Feb 24;14(1):R39.
  8. Pappas DA, Oh C, Plenge R, Greenberg J. Association of Rheumatoid Arthritis Risk Alleles with Response to Anti-TNF Biologics: Results from the CORRONA Registry and Meta-analysis. Inflammation. 2013 Apr;36(2):279-84.
  9. McAllister K, Yarwood A, Bowes J, Orozco G, Viatte S, Diogo D, Hocking LJ, Steer S, Wordsworth P, Wilson AG, Morgan AW; UK Rheumatoid Arthritis Genetics Consortium; Rheumatoid Arthritis Consortium International, Kremer J, Pappas D, Gregersen P, Klareskog L, Plenge R, Barton A, Greenberg J, Worthington J, Eyre S. Meta-analysis identifies BACH2 and RAD51B as rheumatoid arthritis susceptibility loci. Arthritis Rheum. 2013 Sep 10. doi: 10.1002/art.38183. [Epub ahead of print].
  10. Navarro-Millán I, Chen L, Greenberg JD, Pappas DA, Curtis JR. Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients. Semin Arthritis Rheum. 2013 Oct;43(2):137-43.
  11. Okada Y, Wu D, Gosia Trynka, Towfique Raj, Chikashi Terao, Katsunori Ikari, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Robert R. Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, Carroll RJ,. Eyler AE, Greenberg JD, Kremer JM, Pappas DA, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014 Feb 20;506(7488):376-81
  12. Okada Y, Diogo D, Greenberg JD, Mouassess F, Achkar WA, Fulton RS, Denny JC, Gupta N, Mirel D, Gabriel S, Li G, Kremer JM, Pappas DA, et al. Integration of sequence data from a Consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk gene. PLoS One. 2014 Feb 10;9(2):e87645.
  13. Pappas DA, Kremer JM, Reed G, Greenberg JD, Curtis JR. Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients. BMC Musculoskelet Disord. 2014 Apr 1;15:113.
  14. Giles JT, Danoff SK, Sokolove J, Wagner CA, Winchester R, Pappas DA, Siegelman S, Connors G, Robinson WH, Bathon JM. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2014 Aug;73(8):1487-94.
  15. Yarwood A, Han B, Raychaudhuri S, Bowes J, Lunt M, Pappas DA, Kremer J, Greenberg JD, Plenge R; Rheumatoid Arthritis Consortium International (RACI), Worthington J, Barton A, Eyre S. A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Ann Rheum Dis. 2015 Jan;74(1):170-6.
  16. Kim K, Bang SY, Lee HS, Cho SK, Choi CB, Sung YK, Kim TH, Jun JB, Yoo DH, Kang YM, Kim SK, Suh CH, Shim SC, Lee SS, Lee J, Chung WT, Choe JY, Shin HD, Lee JY, Han BG, Nath SK, Eyre S, Bowes J, Pappas DA, et al. High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. Ann Rheum Dis. 2015 Mar;74(3):e13.
  17. Franke L, El Bannoudi H, Jansen DT, Kok K, Trynka G, Diogo D, Swertz M, Fransen K, Knevel R, Gutierrez-Achury J, Ärlestig L, Greenberg JD, Kremer J, Pappas DA, et al. Association analysis of copy numbers of FC-gamma receptor genes for rheumatoid arthritis and other immune-mediated phenotypes. Eur J Hum Genet. 2015 May 13.
  18. Diogo D, Bastarache L, Liao KP, Graham RR, Fulton RS, Greenberg JD, Eyre S, Bowes J, Cui J, Lee A, Pappas DA, et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS One. 2015 Apr 7;10(4):e0122271.
  19. Pappas DA, Hooper MM, Kremer JM, Reed G, Shan Y, Wenkert D, Greenberg JD, Curtis JR. Herpes zoster reactivation in patients with rheumatoid arthritis: Analysis of disease characteristics and disease modifying anti-rheumatic drugs. Arthritis Care Res (Hoboken). 2015 May 27.
  20. Verstappen SM, Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Holmqvist M, Horne L, Lampl K, Michaud K, Nyberg F, Pappas DA, Reed G, Symmons DP, Tanaka E, Tran TN, Yamanaka H, Ho M. Methodological challenges when comparing demographic and clinical characteristics of international observational registries. Arthritis Care Res (Hoboken). 2015 Jul 20.
  21. Nyberg F, Askling J, Berglind N, Franzén S, Ho M, Holmqvist M, Horne L, Lampl K, Michaud K, Pappas DA, et al. Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. Pharmacoepidemiol Drug Saf. 2015 Aug 25.
  22. Pappas DA, Kent JD, Greenberg JD, Mason MA, Kremer JM, Holt RJ. Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based Registry. Rheumatol Ther. 2015 Dec;2(2):153-164
  23. Franke L, El Bannoudi H, Jansen DT, Kok K, Trynka G, Diogo D, Swertz M, Fransen K, Knevel R, Gutierrez-Achury J, Ärlestig L, Greenberg JD, Kremer J, Pappas DA, et al. Association analysis of copy numbers of FC-gamma receptor genes for rheumatoid arthritis and other immune-mediated phenotypes. Eur J Hum Genet. 2016 Feb;24(2):263-70.
  24. Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Michaud K, Nyberg F, Pappas DA, et al.How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. Ann Rheum Dis. 2015 Nov 30. pii: annrheumdis-2015-208105.
  25. Franke L, El Bannoudi H, Jansen DT, Kok K, Trynka G, Diogo D, Swertz M, Fransen K, Knevel R, Gutierrez-Achury J, Ärlestig L, Greenberg JD, Kremer J, Pappas DA, et al. Association analysis of copy numbers of FC-gamma receptor genes for rheumatoid arthritis and other immune-mediated phenotypes. Eur J Hum Genet. 2016 Feb;24(2):263-70.
  26. Michaud K, Berglind N, Franzén S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Nyberg F, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SM, Wesby-van Swaay E, Yamanaka H, Askling J. Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Ann Rheum Dis. 2016 Feb 8. pii: annrheumdis-2015-208698. doi: 10.1136/annrheumdis-2015-208698. [Epub ahead of print]
  27. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Kavanaugh A, Saunders KC, Shan Y, Spruill TM, Pappas DA, Greenberg JD. Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations. Arthritis Res Ther. 2016 Apr 26;18:94
  28. Curtis JR, Bharat A, Chen L, Greenberg JD, Harrold L, Kremer JM, Sommers T, Pappas D. Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry.J Rheumatol. 2016 Jun;43(6):1027-9. doi: 10.3899/jrheum.151136. Epub 2016 May 1.
  29. Cui J, Diogo D, Stahl EA, Canhao H, Mariette X, Greenberg JD, Okada Y, Pappas DA, Fulton RS, Tak PP, Nurmohamed MT, Lee A, Larson DE, Kurreeman F, Deluca TL, O'Laughlin M, Fronick CC, Fulton LL, Mardis ER, van der Horst-Bruinsma IE, Wolbink GJ, Gregersen PK, Kremer JM, Crusius JB, de Vries N, Huizinga TW, Fonseca JE, Miceli-Richard C, Karlson EW, Coenen MJ, Barton A, Plenge RM, Raychaudhuri S. The role of rare protein-coding variants to anti-TNF treatment response in rheumatoid arthritis. Arthritis Rheumatol. 2016 Oct 27. doi: 10.1002/art.39966. [Epub ahead of print]
  30. Sieberts SK, Zhu F, García-García J, Stahl E, Pratap A, Pandey G, Pappas D, et al. Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun. 2016 Aug 23;7:12460. doi: 10.1038/ncomms12460.
  31. Sieberts SK, Zhu F, García-García J, Stahl E, Pratap A, Pandey G, Pappas D, et al. Erratum: Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun. 2016 Oct 10;7:13205. doi: 10.1038/ncomms13205.
  32. Pappas DA, John A, Curtis JR, Reed GW, Karki C, Magner R, Kremer JM, Shewade A, Greenberg JD. Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry. Rheumatol Ther. 2016 Jun;3(1):103-115
  33. Reed GW, Collier DH, Koenig AS, Saunders KC, Pappas DA, Litman HJ, Kremer JM, Kotak S. Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis. Arthritis Res Ther. 2017 Apr 27;19(1):81. doi: 10.1186/s13075-017-1289-x.
  34. Yamanaka H, Kishimoto M, Pappas DA, Greenberg JD, Kremer JM, Tanaka Y.Design characteristics of the Corrona Japan rheumatoid arthritis registry. Mod Rheumatol. 2017 Apr 27:1-6. doi: 10.1080/14397595.2017.1317383. [Epub ahead of print]
  35. Yamanaka H, Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Novelli Horne L, Inoue E, Michaud K, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SMM, Wesby-van Swaay E, Nyberg F. Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. RMD Open. 2017 Oct 10;3(2):e000498. doi: 10.1136/rmdopen-2017-000498. eCollection 2017.
  36. Pappas DA, Kremer JM, Griffith J, Reed G, Salim B, Karki C, Garg V.Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry. Rheumatol Ther. 2017 Dec;4(2):375-389. doi: 10.1007/s40744-017-0077-z. Epub 2017 Aug 24.
  37. Pappas DA, Nyberg F, Kremer JM, Lampl K, Reed GW, Horne L, Ho M, Onofrei A, Malaviya AN, Rillo OL, Radominski SC, Gal J, Gibofsky A, Popkova TV, Laurindo L, Kerzberg EM, Zahora R, Pons-Estel BA, Curtis JR, Furst DE, Greenberg JD. Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. Clin Rheumatol. 2018 Apr 25. doi: 10.1007/s10067-018-4113-3. [Epub ahead of print]
  38. Pappas DA, Gerber RA, Litman HJ, Gruben D, Geier J, Hua WD, Chen C, Li Y, Kremer JM, Andrews JS, Bourret JA. Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry. Am Health Drug Benefits. 2018 May;11(3):148-158.
  39. Curtis JR, Flake DD 2nd, Weinblatt ME, Shadick NA, Østergaard M, Hetland ML, Brahe CH, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas DA, Wang X, Hwang CC, Sasso EH, Gutin A, Hitraya E, Lanchbury JS. Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. Rheumatology (Oxford). 2018 Dec 24. doi: 10.1093/rheumatology/key367. [Epub ahead of print]
  40. Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg MC, Pappas DA, Kremer JM, Solomon DH.Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS One. 2019 Jan 23;14(1):e0210459. doi: 10.1371/journal.pone.0210459. eCollection 2019.
  41. Pappas DA, Rebello S, Liu M, Schenfeld J, Li Y, Collier DH, Accortt NA.Therapy With Biologic Agents After Diagnosis of Solid Malignancies: Results From the Corrona Registry. J Rheumatol. 2019 Apr 1. pii: jrheum.171457. doi: 10.3899/jrheum.171457. [Epub ahead of print]
  42. Pappas DA, Etzel CJ, Zlotnick S, Best J, Blachley T, Kremer JM. Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice. Rheumatol Ther. 2019 Sep;6(3):421-433.
  43. Guan Y, Zhang H, Quang D, Wang Z, Parker SCJ, Pappas DA, Kremer JM, Zhu F. Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers. Arthritis Rheumatol. 2019 Dec;71(12):1987-1996.
  44. Farutin V, Prod'homme T, McConnell K, Washburn N, Halvey P, Etzel CJ, Guess J, Duffner J, Getchell K, Meccariello R, Gutierrez B, Honan C, Zhao G, Cilfone NA, Gunay NS, Hillson JL, DeLuca DS, Saunders KC, Pappas DA, Greenberg JD, Kremer JM, Manning AM, Ling LE, Capila I. Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor. Arthritis Res Ther. 2019 Oct 23;21(1):216.
  45. Pappas DA, Etzel CJ, Crabtree M, Blachley T, Best J, Zlotnick S, Kremer JM. Effectiveness of Tocilizumab in Patients With Rheumatoid Arthritis is Unaffected by Comorbidity Burden or Obesity: Data From a US Registry. J Rheumatol. 2020 Jan 15:jrheum.190282. doi: 10.3899/jrheum.190282. Online ahead of print.
  46. Pappas DA, Blachley T, Zlotnick S, Best J, Emeanuru K, Kremer JM. Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry. Rheumatol Ther. 2020 Jun;7(2):357-369.
  47. Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer JM. Real-World Outcomes Associated with Triple Therapy versus TNFi/MTX Therapy. Arthritis Care Res (Hoboken). 2020 May 6. doi: 10.1002/acr.24253. Online ahead of print.
  48. Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis. 2021 Jan;80(1):96-102. doi: 10.1136/annrheumdis-2020-217209. Epub 2020 Jul 21. PMID: 32719038.
  49. Bergman MJ, Kivitz AJ, Pappas DA, Kremer JM, Zhang L, Jeter A, Withers JB. Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis. Rheumatol Ther. 2020 Dec;7(4):775-792. doi: 10.1007/s40744-020-00226-3. Epub 2020 Aug 14. PMID: 32797404.
  50. Pappas DA, Litman HJ, Lesperance T, Kricorian G, Karis E, Rebello S, Hua W, Accortt NA, Stryker S. Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data. Rheumatol Int. 2021 Feb;41(2):381-390. doi: 10.1007/s00296-020-04667-5. Epub 2020 Sep 2. PMID: 32876744.
  51. Pappas DA, Shan Y, Lesperance T, Kricorian G, Karis E, Rebello S, Hua W, Accortt NA, Stryker S. Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry. ACR Open Rheumatol. 2020 Oct;2(10):588-594. doi: 10.1002/acr2.11168. Epub 2020 Sep 29. PMID: 32990361.
  52. Winthrop KL, Citera G, Gold D, Henrohn D, Connell CA, Shapiro AB, Shi H, Onofrei AM, Pappas DA, Schulze-Koops H. Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry. Ann Rheum Dis. 2021 Jan;80(1):134-136. doi: 10.1136/annrheumdis-2020-218992. Epub 2020 Oct 12. PMID: 33046447. No abstract available.
  53. Kremer JM, Reed G, Pappas DA, Harold LR, Kane K, Greenberg J, Winthrop K. Hydroxychloroquine and the risk of respiratory infections among RA patients. RMD Open. 2020 Nov;6(3):e001389. doi: 10.1136/rmdopen-2020-001389. PMID: 33161375.
  54. Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM. Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng et al. Ann Rheum Dis. 2020 Nov 11:annrheumdis-2020-218907. doi: 10.1136/annrheumdis-2020-218907. Online ahead of print. PMID: 33177102 No abstract available.
  55. Pappas DA, Brittle C, Mossell JE 3rd, Withers JB, Lim-Harashima J, Kremer JM. Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study. Rheumatol Int. 2021 Mar;41(3):585-593. doi: 10.1007/s00296-020-04746-7. Epub 2020 Nov 30. PMID: 33258003.
  56. Kremer JM, Pappas DA, Kane K, Greenberg J, Harrold L, Feathers VL, Shadick N, Weinblatt ME, Reed G. The Clinical Disease Activity Index (CDAI) and the Routine Assessment of Patient Index Data3 (RAPID3) for Achievement of Treatment Strategies. J Rheumatol. 2020 Dec 15:jrheum.200692. doi: 10.3899/jrheum.200692. Online ahead of print. PMID: 33323534.
  57. Petro AD, Dougherty J, England BR, Sayles H, Duryee MJ, Hunter CD, Kremer JM, Pappas DA, Robinson WH, Curtis JR, Thiele GM, Mikuls TR. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis. Int Immunopharmacol. 2021 Feb;91:107260. doi: 10.1016/j.intimp.2020.107260. Epub 2020 Dec 23. PMID: 33360371.
  58. Halvey P, Farutin V, Koppes L, Gunay NS, Pappas DA, Manning AM, Capila I. Variable blood processing procedures contribute to plasma proteomic variability. Clin Proteomics. 2021 Jan 19;18(1):5. doi: 10.1186/s12014-021-09311-3. PMID: 33468058.
  59. Kremer JM, Bingham CO 3rd, Cappelli LC, Greenberg JD, Madsen AM, Geier J, Rivas JL, Onofrei AM, Barr CJ, Pappas DA, Litman HJ, Dandreo KJ, Shapiro AB, Connell CA, Kavanaugh A. Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry. ACR Open Rheumatol. 2021 Feb 11. doi: 10.1002/acr2.11232. Online ahead of print.PMID: 33570260.
  60. Pappas DA, Blachley T, Best JH, Zlotnick S, Reiss WG, Emeanuru K, Kremer JM. Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry. Rheumatol Ther. 2021 Feb 25. doi: 10.1007/s40744-021-00285-0. Online ahead of print.PMID: 33630272.
  61. Harrold LR, Bryson J, Lehman T, Zhuo J, Gao S, Han X, Schrader A, Rebello S, Pappas DA, Sommers T, Kremer JM. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA. Rheumatol Ther. 2021 Jun;8(2):937-953. doi: 10.1007/s40744-021-00310-2. Epub 2021 May 28.PMID: 34047953.
  62. Ocon AJ, Reed G, Pappas DA, Curtis JR, Kremer JM.Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. Ann Rheum Dis. 2021 Jul 2:annrheumdis-2021-220577. doi: 10.1136/annrheumdis-2021-220577. Online ahead of print.PMID: 34215644.
  63. Cohen S, Wells AF, Curtis JR, Dhar R, Mellors T, Zhang L, Withers JB, Jones A, Ghiassian SD, Wang M, Connolly-Strong E, Rapisardo S, Gatalica Z, Pappas DA, Kremer JM, Saleh A, Akmaev VR.A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study. Rheumatol Ther. 2021 Sep;8(3):1159-1176. doi: 10.1007/s40744-021-00330-y. Epub 2021 Jun 19.PMID: 34148193.
  64. Kremer JM, Reed G, Pappas DA, Kane K, Feathers VL, Weinblatt ME, Shadick N, Greenberg J, Harrold LL. Dr. Kremer et al reply. J Rheumatol. 2022 Mar;49(3):338-339. doi: 10.3899/jrheum.210992. Epub 2021 Oct 15. PMID: 34654733.
  65. Curtis JR, Kremer JM, Reed G, John AK, Pappas DA. TNFi Cycling Versus Changing Mechanism of Action in TNFi-Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study. ACR Open Rheumatol. 2022 Jan;4(1):65-73. doi: 10.1002/acr2.11337. Epub 2021 Nov 5. PMID: 34741435; PMCID: PMC8754009.
  66. Alevizos MK, Danoff SK, Pappas DA, Lederer DJ, Johnson C, Hoffman EA, Bernstein EJ, Bathon JM, Giles JT. Assessing predictors of rheumatoid arthritis-associated interstitial lung disease using quantitative lung densitometry. Rheumatology (Oxford). 2022 Jul 6;61(7):2792-2804. doi: 10.1093/rheumatology/keab828. PMID: 34747452.
  67. Pappas DA, Brittle C, Concoff A, Holman AJ, Takasugi D, Kremer JM. Perspectives on applying immuno-autonomics to rheumatoid arthritis: results from an online rheumatologist survey. Rheumatol Int. 2022 Sep;42(9):1555-1564. doi: 10.1007/s00296-022-05122-3. Epub 2022 Apr 21. PMID: 35449236; PMCID: PMC9349152.
  68. Padula AS, Pappas DA, Fiore S, Blachley TS, Ford K, Emeanuru K, Kremer JM. The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry. Arthritis Res Ther. 2022 Dec 21;24(1):276. doi: 10.1186/s13075-022-02955-y. PMID: 36544236; PMCID: PMC9769058.
  69. Curtis JR, Fiore S, Ford K, Janak JC, Chang H, Pappas DA, Blachley T, Emeanuru K, Bykerk VP. Meaningful Improvement and Worsening in Patients Who Do Not Achieve Low Disease Activity and Switch Therapy to a New Biologic or Targeted Disease-Modifying Antirheumatic Drug: Results From the CorEvitas RA Registry. J Clin Rheumatol. 2023 Jun 1;29(4):e47-e51. doi: 10.1097/RHU.0000000000001956. Epub 2023 Mar 24. PMID: 37000177.
  70. Sebba A, Bingham CO, Bykerk VP, Fiore S, Ford K, Janak JC, Pappas DA, Blachley T, Dave SS, Kremer JM, Yu M, Choy E. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry. Clin Rheumatol. 2023 Aug;42(8):2037-2051. doi: 10.1007/s10067-023-06588-7. Epub 2023 Apr 15. PMID: 37060528; PMCID: PMC10345054.
  71. Aripova N, Kremer JM, Pappas DA, Reed G, England BR, Robinson BH, Curtis JR, Thiele GM, Mikuls TR. Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics. Rheumatology (Oxford). 2023 May 30:kead260. doi: 10.1093/rheumatology/kead260. Epub ahead of print. PMID: 37252826.
  72. Pappas DA, O'Brien J, Guo L, Shan Y, Baker JF, Kricorian G, Stryker S, Collier DH. Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry. Arthritis Res Ther. 2023 Sep 9;25(1):166. doi: 10.1186/s13075-023-03120-9. PMID: 37689684; PMCID: PMC10492389.
  73. Cappelli LC, Reed G, Pappas DA, Kremer JM. A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis. Rheumatol Ther. 2023 Dec;10(6):1669-1681. doi: 10.1007/s40744-023-00606-5. Epub 2023 Oct 19. PMID: 37858006; PMCID: PMC10654285.
  74. Dua AB, Ford K, Fiore S, Pappas DA, Janak JC, Blachley T, Roberts-Toler C, Emeanuru K, Kremer JM, Kivitz A. Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study. Rheumatol Ther. 2023 Dec;10(6):1753-1768. doi: 10.1007/s40744-023-00609-2. Epub 2023 Oct 31. PMID: 37906399; PMCID: PMC10654323.
  75. Pappas DA, O'Brien J, Moore PC, Dodge R, Germino R, Masri KR, Bingham CO 3rd, Cappelli LC. Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results From the CorEvitas Rheumatoid Arthritis Registry. J Rheumatol. 2024 May 1;51(5):452-461. doi: 10.3899/jrheum.2023-0752. PMID: 38359941.
  76. Mease P, Reed G, Ogdie A, Pappas DA, Kremer JM. Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Association With Disease Severity Assessment in a Large US Registry. Arthritis Care Res (Hoboken). 2024 Sep;76(9):1313-1321. doi: 10.1002/acr.25358. Epub 2024 Jul 17. PMID: 38736168.
  77. Pappas DA, Reed G, Kane K, Curtis JR, Charles-Schoeman C, Giles JT, Kremer JM. Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients. Semin Arthritis Rheum. 2024 Oct;68:152504. doi: 10.1016/j.semarthrit.2024.152504. Epub 2024 Jun 29. PMID: 38991379.
  78. Baker JF, Reed G, Mikuls TR, Thiele GM, Pappas DA, Charles-Schoeman C, Guma M, Harrold LR, Curtis JR, Kremer JM. Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Rheumatol. 2025 Mar;77(3):263-271. doi: 10.1002/art.43034. Epub 2024 Dec 4. PMID: 39420627; PMCID: PMC11865684.
  79. Razmjou AA, Kremer JM, Pappas DA, Curtis JR, Wang J, Shahbazian A, Elashoff DA, Guo R, Meriwether D, Sulaiman D, O'Connor E, Reddy ST, Charles-Schoeman C. Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins. RMD Open. 2024 Oct 26;10(4):e004829. doi: 10.1136/rmdopen-2024-004829. PMID: 39461874; PMCID: PMC11529732.
  80. Spandorfer R, Kane K, Pappas DA, Kremer J, Reed G, Curtis JR, Navarro-Millán I. New onset work disability in rheumatoid arthritis is an underrecognized cardiovascular risk factor: A retrospective cohort study using the CorEvitas registry. Semin Arthritis Rheum. 2025 Feb;70:152559. doi: 10.1016/j.semarthrit.2024.152559. Epub 2024 Oct 26. PMID: 39550775.

Συγγραφή Βιβλίων, Μονογραφίες

  1. Pappas DA, Bathon JM. (2008). Treatment of Rheumatoid Arthritis: Tumor Necrosis Factor Inhibitors. In Hohcberg MC, Silman AJ, Smolen JS, Weniblatt ME, Weisman MH (Eds), Rheumatoid Arthritis (pp 337-349). Philadephia: Mosby
  2. Pappas DA. Musculoskeletal Ultrasound in Rheumatology. In Current Medical Diagnosis and Treatment ((Rheumatology), McGraw-Hill)) Third Edition, (pp 515-520). Lange
  3. Pappas DA, Kremer JM. Registry Design: Developing Prospective Nested Studies in Existing Registries. In Registries for Evaluating Patient Outcomes. Agency for Healthcare Research and Quality publication Third Edition
  4. Pappas DA, Bathon JM. Rheumatoid Arthritis: Extraarticular manifestations. In Mackay IR, Rose NR (Eds), Encyclopedia of Medical immunology. Springer

Παρουσιάσεις ομιλίες σε διεθνή συνέδρια

  1. Pappas DA. When vertigo turns out to be Sarcoidosis. American College of Physicians, 2005 Annual Scientific meeting, San Fransisco, California, April 2005
  2. Pappas DA, Pappa C, Kremer JM. Giant Cell Arteritis presenting as aortitis and subsequent aortic dissection. American College of Physicians, 2005 Annual New York Chapter Upstate Scientific Meeting, Rochester, New York, October 2005.
  3. Pappas DA, Rodriguez-Pla A, Bathon JM, Giles JT. Glucocorticoid Treatment is Associated with Increased Prevalence of Insulin Resistance In Subjects With Rheumatoid Arthritis. Arthritis and Rheumatism Abstract Supplement 2007; 56(9):S411. American College of Rheumatology National Meeting.
  4. Danoff SK, Pappas DA, Bathon JM. Prevalence Of PFT Abnormalities And Respiratory Symptoms In An RA Patient Cohort. American Thoracic Society, 2008 International Meeting, Toronto, Canada, May 2008.
  5. Pappas DA, Giles JT, Connors G, Lectzin N, Bathon JM, Danoff SK. Respiratory symptoms and disease characteristics as predictors of Pulmonary Function Abnormalities(PFT) in Patients with Rheumatoid Arthritis (RA). Arthritis and Rheumatism Abstract Supplement 2009; 60(10):S359 American College of Rheumatology National Meeting.
  6. Pappas, DA; Greenberg, JD; Stevens, C; Reed, G; Greenstein, N; Flaherty, L; Kremer, JM. Identification of a single nucleolide polymorphism in MIF gene associated with erosive radiographic damage in patients with rheumatoid arthritis. Arthritis Rheum 2005; 52: S146.
  7. Pappas, DA; Greenberg, JD; Stevens, C; Reed, G; Greenstein, N; Flaherty, L; Kremer, JM. Polymorphisms of the uteroglobin gene as a marker of disease activity in rheumatoid arthritis. Arthritis Rheum. 2005; 52: S120.
  8. Pappas, DA; Stevens, C; Greenberg, JD; Reed, G; Greenstein, N; Kremer, JM; Flaherty, L. Identification of single nucleotide polymorphisms in the Mmp3 and SCGB1A1 genes associated with RA susceptibility in a Caucasian population. Arthritis Rheum 2005; 52: S147
  9. Harrington JT, Pappas DA, Messing S, Tu X, Chen R, Kaukeinen K, Pietras T. Dosing of anti-tumor necrosis factor biologics (anti-TNFs) for rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in Clinical Practice in the United States. Arthritis Rheum 2010;62(Suppl 10):1799.
  10. Pappas DA, Rathbun A, Reed G, Kremer JM, Villanueva I, Devenport J, Ogale S. A profile of rheumatoid arthritis patients treated with tocilizumab in a United States registry population. Arthritis Rheum 2011;63(Suppl 10):1262.
  11. Pappas DA, Hooper M, Reed G, Shan Y, Wenkert D, Zhang J, Greenberg J, Curtis J. Risk for herpes zoster after treatment with biologic and synthetic disease modifying agents for rheumatoid arthritis. Ann Rheum Dis 2012;71(Suppl 3):346.
  12. Pappas DA, John A, Greenberg JD, Devenport J, Kremer JM, Ogale S, Reed GW, Saunders KC, Curtis JR. Design characteristics of the CORRONA CERTAIN study: a US comparative effectiveness and biomarkers study of rheumatoid arthritis biologic agents. Ann Rheum Dis 2012;71(Suppl 3):668.
  13. Pala O, Messing S, Hopkins A, Reed G, Perez-Rivera M, Acosta M, Kremer JM, Lozada C, Pappas DA. Effect of alcohol on response to therapy with TNF-A inhibitors for rheumatoid arthritis: results from CORRONA registry. Ann Rheum Dis 2012;71(Suppl 3):369.
  14. Pala O, Messing S, Hopkins A, Reed G, Perez-Rivera M, Acosta M, Kremer JM, Lozada C, Pappas DA. Effect of smoking on response to therapy with the TNF-A inhibitors for Rheumatoid arthritis: results from the CORRONA registry. Ann Rheum Dis 2012;71(Suppl 3):521.
  15. Manno RL, Pappas DA, Saunders KC, Reed GW, Grant S, Bingham CO. Disease-modifying antirheumatic drug use among elderly with rheumatoid arthritis. Arthritis Rheum 2012;64(Suppl 10):2480.
  16. Pappas DA, Reed GW, John A, Shewade A, Saunders KC, Devenport J, Greenberg JD, Kremer JM. Predictors of initiating biologic monotherapy in biologic naïve patients with rheumatoid arthritis (RA) in a United States registry population. Arthritis Rheum 2012;64(Suppl 10):491.
  17. Pappas DA, Reed GW, Saunders KC, John A, Shewade A, Devenport J, Greenberg JD, Kremer JM. Characteristics associated with biologic initiation as monotherapy versus combination Therapy in patients with rheumatoid arthritis (RA) in a United States registry population. Arthritis Rheum 2012;64(Suppl 10):557.
  18. Pappas DA, Lampl K, Kremer JM, Nyberg F, Gibofsky A, Ho M, Horne L, Saunders K, Onofrei AU, Greenberg JD. The CORRONA international rheumatoid arthritis registry: variations in disease activity and management across participating regions. Ann Rheum Dis 2013;72(Suppl 3):209.
  19. Pappas DA, John A, Curtis JR, Kremer J, Reiss W, Shewade A, Silverman GJ, Greenberg JD. Prevalence of low immunoglobulin levels and associations with rheumatoid arthritis factors. Ann Rheum Dis 2013;72(Suppl 3):448.
  20. Pappas DA, John A, Kremer J, Reed G, Greenberg JD, Shewade A, Solomon DH, Curtis JR. Effect of biologic agents on lipids and cardiovascular risk in rheumatoid arthritis patients. Ann Rheum Dis 2013;72(Suppl 3):49.
  21. Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg M, Pappas D, Kremer JM, Solomon DH. Use of TNF inhibitors is associated with a reduced risk of diabetes in RA patients. Ann Rheum Dis 2013;72(Suppl 3):106.
  22. Pappas DA, Kremer J, Greenberg J, Shewade A., Solomon D, Curtis JR. Dyslipidemia, inflammation and cardiovascular risk in patients with rheumatoid arthritis. International Conference on Pharmacoepidemiology and Therapeutic Risk Management 25-28 August 2013. Montreal, Canada.
  23. Yamanaka H, Askling J, Berglind N, Franzén S, Frisell T, Garwood C. Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Lampl K, Michaud K, Pappas DA, Reed G, Symmons D, Tanaka E, Tran T, Verstappen S, Nyberg F. Rates of hospitalized infections in rheumatoid arthritis patients from 5 rheumatoid arthritis registries across the world. Arthritis Rheum 2013;65(Suppl 10):1047.
  24. Pappas DA, Lampl K, Kremer JM, Radominski SC, Gal J, Nyberg F, Malaviya A, Whitworth A, Rillo O, Gibofsky A, Popkova T, Ho M, Laurindo I, Reed GW, Kerzberg E, Horne L, Zahora R, Saunders K, Pons-Estel B, Onofrei AU, Greenberg JD. Variations in disease activity and therapeutic management of RA in different international regions. Data from the CORRONA International and CORRONA US registries. Arthritis Rheum 2013;65(Suppl 10):1303.
  25. Pappas DA, Chen L, Harrold LR, Reed G, Kremer J, Greenberg JD, Curtis JR. Physician variability in rheumatoid patients not receiving biologics or non-biologic DMARDs: implications for quality reporting. Arthritis Rheum 2013;65(Suppl 10):193.
  26. Pappas DA, John A, Curtis JR, Reed GW, Sommers T, Greenberg JD, Shewade A, Solomon DH, Kremer JM. Effect of biologic agents on lipids and cardiovascular risk in rheumatoid arthritis patients. Arthritis Rheum 2013;65(Suppl 10):2827.
  27. Pappas DA, John A, Curtis JR, Reed GW, Sommers T, Greenberg JD, Shewade A, Kremer JM. Shift in cardiovascular risk and lipid levels in rheumatoid arthritis using ATP-3 guidelines: CORRONA CERTAIN study. Arthritis Rheum 2013;65(Suppl 10):370.
  28. Pappas DA, John A, Kremer JM, Karki CK, Sommers T, Reed GW, Curtis JR, Shewade A, Greenberg JD. Effect of tocilizumab on treatment patterns, effectiveness and safety with laboratory values for patients with rheumatoid arthritis: analyses from the CORRONA – CERTAIN Study. Arthritis Rheum 2013;65(Suppl 10):2344.
  29. Pappas DA, John A, Kremer JM, Reed GW, Sommers T, Greenberg JD, Shewade A, Curtis JR. Management of hyperlipidemia in patients with rheumatoid arthritis: results from the CORRONA CERTAIN study. Arthritis Rheum 2013;65(Suppl 10):362.
  30. Pappas DA, Karki CK, Lee C, Reed GW, He P, Al Sawah S. Patient reported pain: a predictor of outcomes in rheumatoid arthritis from the Consortium of Rheumatology Researchers of North America (CORRONA) registry. Arthritis Rheum 2013;65(Suppl 10):2269.
  31. Pappas DA, Lampl K, Kremer JM, Radominski SC, Gal J, Nyberg F, Malaviya A, Whitworth A, Rillo O, Gibofsky A, Popkova T, Ho M, Laurindo I, Reed GW, Kerzberg E, Horne L, Zahora R, Saunders K, Pons-Estel B, Onofrei AU, Greenberg JD. Prevalence of cardiovascular risk factors and cardiovascular disease in different international regions. Data from the CORRONA International and CORRONA US registries. Arthritis Rheum 2013;65(Suppl 10):392.
  32. Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold LR, Hochberg MC, Pappas DA, Kremer JM, Solomon DH. Use of TNF inhibitors is associated with a reduced risk of diabetes in RA patients. Arthritis Rheum 2013;65(Suppl 10):1040.
  33. Hopkins A, Martinez-Marti A, Reed G, He P, Greenberg JD, Lozada C, Pala O, Kremer JM, Pappas DA. Effectiveness of TNF-á inhibitor therapy does not differ between elderly and younger patients with rheumatoid arthritis: results from the CORRONA registry. Arthritis Rheum 2013;65(Suppl 10):1435.
  34. Dimitrios Pappas, Carol Etzel, Angela Bedenbaugh, Jeymi Tambiah, Jeff Greenberg. Baseline characteristics of elderly RA patients treated with Certolizumab Pegol and other TNF-a inhibitors. Results from the CORRONA registry. International Society For Pharmacoeconomics and Outcomes Research. Montreal, Canada. 31, May – 4 June 2014.
  35. Pappas DA, John A, Reed GW, Karki C, Greenberg JD, Shewade A, Kremer JM. Persistency and its predictors of biologic monotherapy in patients with RA: analyses from the CORRONA RA registry. Ann Rheum Dis 2014;73(Suppl2):496-497.
  36. Pappas DA, Lampl K, Kremer JM, Radominski SC, Gal J, Nyberg F, Malaviya A, Whitworth A, Rillo O, Gibofsky A, Popkova T, Ho M, Laurindo I, Reed GW, Kerzberg E, Horne L, Zahora R, Saunders K, Pons-Estel B, Onofrei AU, Greenberg JD. Prevalence of cardiovascular risk factors and cardiovascular disease in rheumatoid arthritis patients across international regions: a comparison of the CORRONA International and CORRRONA US registries. Ann Rheum Dis 2014;73(Suppl2):639.
  37. Pappas DA, Lampl K, Kremer JM, Radominski SC, Gal J, Nyberg F, Malaviya A, Whitworth A, Rillo O, Gibofsky A, Popkova T, Ho M, Laurindo I, Reed GW, Kerzberg E, Horne L, Zahora R, Saunders K, Pons-Estel B, Onofrei AU, Greenberg JD. Variations in disease activity and therapeutic management of rheumatoid arthritis in different international regions: a comparison of data from the CORRONA International and CORRONA RA registries. Ann Rheum Dis 2014;73(Suppl2):400.
  38. Pappas DA, Shaw J, Chang H, Cifaldi M, Reed GW, Garg V, Lacerda A, Mozaffarian N. Laboratory safety of adalimumab and other tumor necrosis factor inhibitors in the treatment of rheumatoid arthritis. Ann Rheum Dis 2014;73(Suppl2):931.
  39. Pappas DA, John A, Curtis JR, Reed GW, Karki C, Magner R, Kremer JM, Shewade A, Greenberg JD. Dosing of intravenous tocilizumab in a real-world setting—analyses from a US RA registry. Arthritis Rheum 2014;66(Suppl11):515.
  40. Pappas DA, Kent JD, Kremer JM, Mason M, Grahn AY, Greenberg JD, Holt RJ. Characteristics of rheumatoid arthritis patients not receiving early initiation of disease modifying therapy. Arthritis Rheum 2014;66(Suppl11):2415.
  41. Curtis JR, Bharat A, Chen L, Greenberg JD, Kremer J, Pappas D. Physician awareness of suboptimal patient adherence to MTX: results from a large U.S. rheumatoid arthritis registry. Arthritis Rheum 2014;66(Suppl11):2367.
  42. Pappas DA, John A, Curtis JR, Etzel CE, Karki C, Ssemakula J, Kremer JM, Shewade A, Greenberg JD. Patterns of biologic discontinuations within the Corrona registry: CERTAIN study. Ann Rheum Dis2015;74(Suppl2):1044.
  43. Pappas D, Reed GW, Bao Y, Grant SP, Garg V. Impact of biologic discontinuation in patients with rheumatoid arthritis: observation from the Corrona registry. Ann Rheum Dis2015;74(Suppl2):226.
  44. Pappas DA, Griffith J, Karki C, Liu M, Kremer JM, Ganguli A, Greenberg JD. The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2015; 67 (suppl 10).
  45. Pappas DA, Holt RJ, Shan Y, Kent JD, Nguyen JT, Kremer JM, Greenberg JD. The Influence of Patient Reported Morning Stiffness on Patient Global Assessment in Rheumatoid Arthritis Patients Not Achieving ACR/EULAR Boolean Remission in a Large US Registry. Arthritis Rheumatol. 2015; 67 (suppl 10).
  46. Pappas DA, John A, Etzel CJ, Karki C, Li Y, Kremer JM, Haselkorn T, Greenberg JD. Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry. Arthritis Rheumatol. 2015; 67 (suppl 10).
  47. Pappas DA, Karki C, Liu M, Kremer JM, Greenberg JD, Garg V. Delay in initiation of biologics among bio-eligible patients with rheumatoid arthritis in US: Evidence from the Corrona registry. Ann Rheum Dis2016;75(Suppl2): 248.
  48. Pappas DA, John A, Kremer JM, Reed GW, Sommers T, Greenberg JD, Curtis JR. Comparative Effectiveness of Biologic Agents for Patients with Rheumatoid Arthritis—Primary Analysis from the US Corrona CERTAIN Study. Ann Rheum Dis2016;75(Suppl2): 1020.
  49. Pappas DA, Karki C, Litman HJ, Greenberg JD, Garg V, Kremer JM. Need to advance therapy in rheumatoid arthritis patients treated with triple nbDMARD vs biologic combination therapy: Results from the Corrona registry. Ann Rheum Dis2016;75(Suppl2): 249
  50. Harrold LR, Palmer JL, Pappas DA, Kremer JM, Greenberg JD. Trends in the achievement of low disease activity among a US National sample of RA pts initiating biologics. Ann Rheum Dis2016;75(Suppl2): 199.
  51. Pappas DA, Griffith J, Litman HJ, Schlacher CA, Salim BA, Karki C, Kremer JM. Time to Initiation of Biologic Agents Is Associated with Glucocorticoid Use: Results from the Corrona Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).
  52. Pappas DA, Rebello S, Liu M, Schenfeld J, Li Y, Collier DH, Accortt N. Therapy with Biologic Agents after Diagnosis of Solid Malignancies; Results from the Corrona Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).
  53. Pappas DA, Griffith J, Schlacher C, Shan Y, Karki C, Kremer JM. Effectiveness of Low and High Dose Methotrexate in Combination with Adalimumab in a Real World Setting: Results from the Corrona Rheumatoid Arthritis Registry. Ann Rheum Dis2017;76(Suppl2): 827. Poster
  54. Pappas DA, Griffith J, Schlacher C, Suboticki JL, Harrison R, Shan Y, Karki C, Kremer JM. Effectiveness of Adalimumab Combination Therapy with Methotrexate and Non-Methotrexate csDMARDs: Results from the Corrona Rheumatoid Arthritis Registry. Ann Rheum Dis2017;76(Suppl2): 552. Poster
  55. Pappas DA, Reed GW, Zlotnick S, Best J, Magner R, Persuitte G, Greenberg JD. Repeated Rituximab Infusions for the Therapy of Rheumatoid Arthritis is not Associated with Increased Rates of Serious Infections. Ann Rheum Dis2017;76(Suppl2): 846. Poster
  56. Pappas DA, Sasso EH, Bolce RJ, Liu X, Etzel CJ. The Multi-Biomarker Disease Activity (MBDA) Score for Assessing Response to Treatment with Adalimumab. Ann Rheum Dis2017;76(Suppl2): 1121. Publication
  57. Pappas DA, Etzel CJ, Best J, Zlotnick S, Blachley T, Persuitte G, Kremer JM. Patterns of Prednisone Use in US Patients With Rheumatoid Arthritis Initiating Treatment With Tocilizumab in Routine Clinical Practice. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster
  58. Pappas DA, Karki C, Litman HJ, Blachley T, Suboticki JL, Griffith J, Kremer JM. Impact of Adalimumab on Prednisone Use in Patients with Rheumatoid Arthritis in a Real World Setting – Results from Corrona Registry. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster
  59. Pappas DA, Karki C, Shan Y, Suboticki JL, Griffith J, Kremer JM. Methotrexate Discontinuation from Combination Therapy with Adalimumab is not Associated with Inferior Outcomes at 6 Months. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster
  60. Pappas DA, Murray J, Etzel CJ, Nelson D, Gershenson B, Saunders KC, Rebello S, Kremer JM. Rheumatoid Arthritis Patient Characteristics Also Predict Response to Therapy with Biologic Agents: Results from the Corrona CERTAIN Study. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster
  61. Pappas DA, Reed GW, Karki C, Griffith J, Skup M, Garg V, Kremer J. Real-world Consistency of Response to Adalimumab Over Time in Patients With Rheumatoid Arthritis: Results From the Corrona Registry. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster
  62. Pappas DA, Reed GW, Zlotnick S, Best J, Magner R, Persuitte G, Greenberg JD. Repeated Rituximab Infusions for the Therapy of Rheumatoid Arthritis Is Not Associated With Increased Rates of Serious Infections. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster
  63. Farutin V, Prod’homme T, McConnell K, Halvey P, Washburn N, Cilfone N, Kyriakis S, Hillson J, Etzel CJ, Saunders KC, Pappas DA, Manning A, Ling L, Capila I. Molecular Profiling of RA Patients Suggests a Differential Involvement of Adaptive and Innate Cell Populations in Response to Anti-TNF Treatment. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster
  64. Pappas DA, Etzel CJ, Crabtree M, Best J, Zlotnick S, Kremer JM. Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis. Ann Rheum Dis2018;**(Suppl*): *** .Poster
  65. Pappas DA, Litman HJ, Lesperance T, Rebello S, Karis E, Kricorian G, Hua D, Accortt NA. Persistence on Tumor Necrosis Factor Inhibitor (TNFi) Monotherapy Among Patients with Rheumatoid Arthritis (RA) in Remission or Low Disease Activity (LDA). Ann Rheum Dis2018;77(Suppl): A600 .Poster
  66. Pappas DA, Saunders KC, Etzel CJ, Hua DW, Deering K, Zueger P, Garg V. Evaluation of the Use of Ultrasound to Manage Patients With Rheumatoid Arthritis Over Time: Results From the Corrona Registry. Ann Rheum Dis2018;77(Suppl): A906 .Poster
  67. Pappas DA, Etzel CJ, Crabtree M, Best JH, Zlotnick S, Kremer J. Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). Poster
  68. Pappas DA, Shan Y, Lesperance T, Rebello S, Karis E, Kricorian G, Hua W, Accortt NA, Stryker S. Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). Poster
  69. Pappas DA, St. John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Boklage S, Kremer J. The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).
  70. Pappas DA, Tundia N, Shan Y, Litman HJ, Kremer J. Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). Poster
  71. Mikuls TR, Bath A, England BR, Duryee MJ, Hunter CD, Kremer J, Pappas DA, Robinson WH, Curtis JR, Thiele GM. Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).
  72. Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer J. Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).
  73. Pappas DA, Blachley T, Zlotnick S, Best J, Emeanuru K, Kremer JM. Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A1150. Poster
  74. Kremer J, Bingham C, Cappelli L, Etzel C, Greenberg J, Geier J, Madsen A, Chen C, Onofrei A, Barr C, Pappas DA, Litman HJ, Dandreo KJ, Shapiro A, Connell CA, Kavanaugh A. Post-Approval Comparative Safety Study Of Tofacitinib And Biologic Dmards: Five Year Results From A Us-Based Rheumatoid Arthritis Registry. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A82. Presentation
  75. Pappas D, Blachley T, Zlotnick S, Best J, Emeanuru K, Kremer J. Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).
  76. Pappas D, Blachley T, Zlotnick S, Best J, Emeanuru K, Kremer J. Comparative Effectiveness of Tocilizumab in Combination with Methotrexate versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination with Methotrexate in Patients with Rheumatoid Arthritis with Prior Exposure to TNFis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).
  77. Pappas D, Blachley T, Best J, Zlotnick S, Emeanuru K, Kremer J. Persistence of Tocilizumab Therapy Among Patients with Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).
  78. Kremer J, Bingham C, Cappelli L, Greenberg J, Geier J, Madsen A, Chen C, Onofrei A, Barr C, Pappas D, Litman H, Dandreo K, Shapiro A, Connell C, Kavanaugh A. Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).
  79. Kremer J, Bingham C, Cappelli L, Greenberg J, Madsen A, Geier J, Rivas J, Onofrei A, Barr C, Pappas D, Litman H, Dandreo K, Shapiro A, Connell C, Kavanaugh A. Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).
  80. Pappas DA, Blachley T, Zlotnick S, Best J, Emeanuru K, Kremer JM. Comparative Effectiveness of Tocilizumab in Combination With Methotrexate Versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination With Methotrexate in Patients With Rheumatoid Arthritis With Prior Exposure to TNFis. June 2020 Volume 79 Supplement 1. DOI: 10.1136/annrheumdis-2020-eular.588. Poster
  81. Pappas DA, Blachley T, Best J, Zlotnick S, Emeanuru K, Kremer JM. Persistence of Tocilizumab Therapy Among Patients With Rheumatoid Arthritis: Data From the US-Based Corrona Rheumatoid Arthritis Registry. June 2020 Volume 79 Supplement 1. DOI: 10.1136/annrheumdis-2020-eular.708. Poster
  82. Pappas DA, Blachley T, Best J, Zlotnick S, Reiss W, Emeanuru K, Kremer JM. Durability of Response Among Patients With Rheumatoid Arthritis Initiating Tocilizumab: Data From the US-Based Corrona Rheumatoid Arthritis Registry. June 2020 Volume 79 Supplement 1. DOI: 10.1136/annrheumdis-2020-eular.571. Poster
*Selected as one of the highlighted abstracts of the meeting

Άλλα Μέσα Ενημέρωσης (βίντεο, CD-ROMs, παρουσιάσεις, κτλ.)

  1. Ask the expert educational videos. The Johns Hopkins Arthritis Center Website. Pappas DA, Ruffing V. Ultrasound and Rheumatoid Arthritis. http://www.hopkins-arthritis.org/ask-the-expert/video/
  2. Ask the expert educational videos. The Johns Hopkins Arthritis Center Website: Pappas DA, Ruffing V. Symptoms of Rheumatoid Arthritis. http://www.hopkins-arthritis.org/ask-the-expert/video/
  3. Ask the expert educational videos. The Johns Hopkins Arthritis Center Website: Pappas DA, Ruffing V. How to locate a rheumatologist. http://www.hopkins-arthritis.org/ask-the-expert/video/
  4. WEBMD: Pappas DA. Biologic treatment in Rheumatoid Arthritis. Ask the expert video. http://www.webmd.com/rheumatoid-arthritis/biologics-10/choosing-biologics-video
  5. CBS television broadcast: Musculoskeletal Ultrasound in Rheumatology: Pappas DA
    CBS new York: http://newyork.cbslocal.com/video/7031241-dr-max-gomez-arthritis-ultrasounds
    CBS Pitssburgh: http://pittsburgh.cbslocal.com/2012/04/20/ultrasound-offering-arthritis-patients-some-relief
    *this story was broadcasted in several states by CBS
  6. CBS Radio Broadcast: The Osgood File – Ultrasound for Arthritis http://www.westwood-backup.com/pg/jsp/osgood/transcript.jsp?pid=34091

ΔΙΔΑΣΚΑΛΙΑ

Διδασκαλία σε τάξη

2012 – Σήμερα

Μαθήματα Επιδημιολογίας Χρονίων Νόσων για φοιτητές μεταπτυχιακού προγράμματος Επιδημιολογίας, Πανεπιστήμιο Columbia, Σχολή Mailman Δημόσιας Υγείας

2010 – Σήμερα

Διδασκαλία Παθοφυσιολογίας για τους Φοιτητές Ιατρικής του Πανεπιστημίου Columbia, Πανεπιστήμιο Columbia, College of Physicians and Surgeons

2010 – Σήμερα

Μαθήματα Ρευματολογίας για τους ειδικευόμενους Εσωτερικής Παθολογίας, Πανεπιστήμιο Columbia, College of Physicians and Surgeons

2010 – Σήμερα

Μαθήματα Ρευματολογίας για ειδικευόμενους της Φυσιατρικής και Αποκατάστασης, Πανεπιστήμιο Columbia, College of Physicians and Surgeons
 

Κλινική Διδασκαλία

2010 – Σήμερα

Μαθήματα Μυοσκελετικού Υπερήχου για ειδικευόμενους Ρευματολογίας, πανεπιστήμιο Columbia

2009 – 2010

Μαθήματα Μυοσκελετικού Υπερήχου για ειδικευόμενους Ρευματολογίας, πανεπιστήμιο Johns Hopkins

ΚΛΙΝΙΚΗ ΔΡΑΣΤΗΡΙΟΤΗΤΑ

Άδειες Ασκήσεως Επαγγέλματος

2010 – Σήμερα

Πολιτεία Νέα Υόρκης, Η.Π.Α. (Αριθμός μητρώου: 003727-1)

2009 – 2010

Πολιτεία Μέρυλαντ, Η.Π.Α. (Αριθμός Μητρώου: DOO 68969)

Αναγνώριση Εκπαίδευσης Ειδικοτήτων στις Η.Π.Α.

2009

Musculoskeletal Ultrasound School of North America for Rheumatologists (Musculoskeletal Ultrasound for Rheumatology): Εξειδίκευση στο Μυοσκελετικό Υπέρηχο

2009

American Board of Internal Medicine (Rheumatology): Ειδικότητα Ρευματολογίας

2006

American Board of Internal Medicine: Ειδικότητα Εσωτερικής Παθολογίας

2003

Educational Commission for Foreign Medical Graduates /ECFMG: Ιατρική Πτυχιακή Εκπαίδευση

ΔΙΟΙΚΗΤΙΚΗ ΔΡΑΣΤΗΡΙΟΤΗΤΑ

Διοικητικές Θέσεις

2010 – Σήμερα

Διευθυντής, Κέντρο Ρευματολογικού Μυοσκελετικού Υπερήχου - Fast Arthritis Sonographic Evaluation and Treatment (FAST) Center, Διεύθυνση Παθολογίας, Τομέας Ρευματολογίας, Πανεπιστήμιο Columbia, Νέα Υόρκη, Νέα Υόρκη, Η.Π.Α.

2009 – 2010

Συνδιευθυντής, Κέντρο Ρευματολογικού Μυοσκελετικού Υπερήχου – Rapid Arthritis Care and Evaluation (RACE) Center, Διεύθυνση Παθολογίας, Τομέας Ρευματολογίας, Πανεπιστήμιο Johns Hopkins, Βαλτιμόρη, Μέριλαντ, Η.Π.Α.

ΣΥΝΤΑΚΤΙΚΕΣ ΔΡΑΣΤΗΡΙΟΤΗΤΕΣ

Επιστημονική Επιτροπή σε Περιοδικά

2010 – Σήμερα

US Musculoskeletal Review

2010 – Σήμερα

Lupus

2008 – Σήμερα

Arthritis and Rheumatism

2008 – Σήμερα

Arthritis Care and Research

2008 – Σήμερα

The American Journal of Medicine

Συμβουλευτικές και Επιστημονικές Επιτροπές

2011 – Σήμερα

Επιστημονικός Διευθυντής – CORRONA International, Consortium of Rheumatology Researchers of North America.

2010 – Σήμερα

Επιστημονικός Διευθυντής – CORRONA CERTAIN study, Consortium of Rheumatology Researchers of North America.

2010 – Σήμερα

Επιστημονικός Διευθυντής – Consortium of Rheumatology Researchers of North America (CORRONA).

Επαγγελματικές Ενώσεις

2009 – Σήμερα

Μέλος, American Medical Association

2008 – Σήμερα

Μέλος, Arthritis Foundation

2006 – Σήμερα

Μέλος, American College of Rheumatology

2004 – Σήμερα

Μέλος, American College of Physicians

1999 – Σήμερα

Μέλος, Ελληνικός Ιατρικός Σύλλογος

ΑΝΑΓΝΩΡΙΣΗ

Βραβεία/Υποτροφίες

2006 -07

Ταξιδιωτική υποτροφία του Αμερικανικού Κολλεγίου Ρευματολογίας (American College of Rheumatology ACR-FIT scholarship).

2005

Ερευνητικό βραβείο και χρηματοδότηση του Ιδρύματος Αρθρίτιδας του Μέριλαντ (MARRC Senior Fellowship, Arthritis Foundation, Maryland Chapter).

2004

Πρώτο βραβείο έρευνας ειδικευομένων Παθολογίας του Ιατρικού Κολλεγίου του Ώλμπανυ (Albany Medical College – Union University Housestaff Research Award).

2003

Πρώτο βραβείο στο διαγωνισμό πόστερ του Αμερικανικού Κολλεγίου Παθολογίας (ACP Poster Finalist, National Associates Clinical Associate Poster Competition)

Προσκεκλημένος Ομιλητής

2012

Συμμετοχή σε επιστημονικό πάνελ: CORRONA Επιστημονική Συμβουλευτική Επιτροπή, Σικάγο, Ιλινόι, Η.Π.Α.

2011

Ομιλητής, SPAR Rheumatology Meeting “Rheumatoid Arthritis and Cardiovascular Risk Factors”, Μοντερέι, Καλιφόρνια, Η.Π.Α.

2011

Συμμετοχή σε επιστημονικό πάνελ: AHRQ Outcome Initiative: Registries of Patient Registries Ουάσιγκτον, Περιφέρεια της Κολούμπια, Η.Π.Α.

2011

Ομιλητής, Στρογγυλή Τράπεζα: Μυοσκελετικός Υπέρηχος, American College of Rheumatology, Ουάσιγκτον, Περιφέρεια της Κολούμπια, Η.Π.Α.

2010

Ομιλητής, RNS national meeting, “Patient reported outcomes”, Σικάγο, Ιλινόι, Η.Π.Α.

2010

Ομιλητής, Πανεπιστήμιο Αθηνών, Joint Training Program on Systemic Rheumatic Diseases, “Respiratory Involvement in Rheumatoid Arthritis”, Αθήνα, Ελλάδα

2010

Ομιλητής, Weill Cornell University, Lincoln Hospital, “Rheumatoid Arthritis in the era of biologic agents”, Νέα Υόρκη, Νέα Υόρκη, Η.Π.Α.